August 2026

Federal Minister for Commerce Jam Kamal Khan chaired a high-level review, directing Foreign Trade Wings to formulate country-specific plans prioritizing pharmaceutical exports. The initiative focuses on resolving market-access barriers, improving trade logistics, and leveraging international trade missions to boost Pakistani pharma globally.

Pakistan is moving toward WHO Maturity Level-3 accreditation by April 2027—a landmark step announced by Health Minister Syed Mustafa Kamal. PPMA fully supports DRAP and the Ministry of Health in unlocking new international trade opportunities and setting global regulatory standards.

The Cabinet Committee for Drug Pricing, chaired by Finance Minister Muhammad Aurangzeb, has approved Maximum Retail Prices (MRPs) for 52 new advanced molecules targeting Cancer, Diabetes, and Hypertension.This major milestone brings the total approved essential drugs to 87 in just 4 months. Official notification will pave the way for local production and unlock strong potential

PPMA presented the pharmaceutical industry’s perspective on key sector issues, including the deregulation of non-essential medicines. The meeting was presided over by Senator Aamir Chishti, Chairman of the Standing Committee.

DRAP has officially issued draft amendments regarding the Drugs Labelling and Packing Rules and is requesting feedback from stakeholders. We urge all pharmaceutical manufacturers to review the draft to support:✅ Supply-chain software integration✅ Regulatory compliance✅ Patient safetyStay proactive and share your valuable inputs today.